DDInter178 DDInter1105
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lurbinectedin {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lurbinectedin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lurbinectedin may lead to a major life threatening interaction when taken with Ribociclib
Lurbinectedin may lead to a major life threatening interaction when taken with Upadacitinib